AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Allsci

Published November 13, 2026 · Updated November 14, 2026

ARPA-H awards up to USD 4.9m to establish ibogaine clinical trial framework for PTSD

Read the full story at Allsci

Ibogaine is a plant-derived psychoactive alkaloid that acts on multiple neurotransmitter systems and has been investigated primarily for opioid.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine